CoChat

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes

Open access
Schernthaner, Guntram, Shehadeh, Naim, Ametov, Alexander S., Bazarova, Anna V., Ebrahimi, Fahim, Fasching, Peter, Janež, Andrej, Kempler, Péter, Konrāde, Ilze, Lalić, Nebojša M., Mankovsky, Boris, Martinka, Emil, Rahelić, Dario, Serafinceanu, Cristian, Škrha, Jan, Tankova, Tsvetalina, Visockienė, Žydrūnė · 2020 · Cardiovascular Diabetology
Cited by 164

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed to herald a new era in the management of type 2 diabetes (T2D), especially for the many patients with T2D who are at high risk for cardiovascular and renal events. However, as the evidence in favour of various sodium–glucose transporter-2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) accumulates, prescriptions of these agents continue to stagnate, even among eligible, at-risk patients. By contrast, dipeptidyl peptidase-4 inhibitors (DPP-4i) DPP-4i remain more widely used than SGLT2i and GLP-1 RA in these patients, despite a similar cost to SGLT2i and a large body of evidence showing no clear benefit on cardiorenal outcomes. We are a group of diabetologists united by a shared concern that clinical inertia is preventing these patients from receiving life-saving treatments, as well as placing them at greater risk of hospitalisation for heart failure and progression of renal disease. We propose a manifesto for change, in order to increase uptake of SGLT2i and GLP-1 RA in appropriate patients as a matter of urgency, especially those who could be readily switched from an agent without proven cardiorenal benefit. Central to our manifesto is a shift from linear treatment algorithms based on HbA1c target setting to parallel, independent considerations of atherosclerotic cardiovascular disease, heart failure and renal risks, in accordance with newly updated guidelines. Finally, we call upon all colleagues to play their part in implementing our manifesto at a local level, ensuring that patients do not pay a heavy price for continued clinical inertia in T2D.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-020-01154-w

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 164

Metadata

Authors
Schernthaner, G., Shehadeh, N., Ametov, A. S., Bazarova, A. V., Ebrahimi, F., Fasching, P., Janež, A., Kempler, P., Konrāde, I., Lalić, N. M., Mankovsky, B., Martinka, E., Rahelić, D., Serafinceanu, C., Škrha, J., Tankova, T., & Visockienė, Ž.
Venue
Cardiovascular Diabetology
Published
2020-10-23
Volume
19
Issue
1
Pages
185-185
ISSN
1475-2840 (ISSN-L)
OpenAlex
W3093773039
Cited by
164
References
36
FWCI
16.40
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. https://app.cochat.ai/papers/10.1186/s12933-020-01154-w
The paper
Schernthaner, G., Shehadeh, N., Ametov, A. S., Bazarova, A. V., Ebrahimi, F., Fasching, P., Janež, A., Kempler, P., Konrāde, I., Lalić, N. M., Mankovsky, B., Martinka, E., Rahelić, D., Serafinceanu, C., Škrha, J., Tankova, T., & Visockienė, Ž. (2020). Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-020-01154-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.